Developer of drugs for the treatment of inflammatory and thrombotic diseases. The company's treatment program is built around an antibody called SelK2 directed against the cell adhesion molecule P-Selectin Glycoprotein Ligand-1 (PSGL-1).
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
04/18/2018 | Series B | $63.95MM | $xx.xx | $36.67B | Mpm Capital, Philip Jones | |
Price per Share
$xx.xx
Shares Outstanding
3,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Mpm Capital, Philip Jones
|
||||||
02/09/2015 | Series A | $4.69MM | $xx.xx | $1.17B | I2e | |
Price per Share
$xx.xx
Shares Outstanding
7,004,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
I2e
|